RALOXIFENE HCL
ANTIESTROGEN · PREVENTION OF BREAST CANCER IN HIGH RISK WOMEN ·+2
MODAVAR PHARMAC
Drug class
Osteoporosis Agents
Osteoporosis agents comprise a broad therapeutic category of medications used to prevent bone loss, increase bone mineral density, and reduce fracture risk. Read more about Osteoporosis Agents
114 drugs in this class 61 manufacturers
Drugs in Osteoporosis Agents
ZOLEDRONIC ACID (zoledronic acid in mannitol and water for injection)
HYPERCALCEMIA AGENTS · PAGET'S DISEASE OF BONE ·+5
FOSUN PHARMA US
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
EXELAN PHARMACE
TERIPARATIDE
OSTEOPOROSIS AGENTS · GLUCOCORTICOID-INDUCED OSTEOPOROSIS ·+2
TEVA USA
CALCITONIN-SALMON (calcitonin,salmon,synthetic)
HYPERCALCEMIA AGENTS · HYPERCALCEMIA TREATMENT ADJUNCT ·+2
LEUCADIA/HIKMA
CALCITONIN-SALMON (calcitonin,salmon,synthetic)
HYPERCALCEMIA AGENTS · HYPERCALCEMIA TREATMENT ADJUNCT ·+2
PAR HEALTH USA,
ZOLEDRONIC ACID
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+2
Avet Pharmaceuticals
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
Hikma Pharmaceuticals USA
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
NOVITIUM/ANI PH
Filter & compare in the drug finder →
Opens the drug finder with Osteoporosis Agents preselected. Add indication or manufacturer filters there.
Osteoporosis agents comprise a broad therapeutic category of medications used to prevent bone loss, increase bone mineral density, and reduce fracture risk.
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation.
Clinically, these agents are primarily indicated for the management and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss.
-
fda.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
Clinically, these agents are primarily indicated for the management and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.